Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models
Tofacitinib reduced the IFN signature, and survival in this group did not differ significantly from healthy controls, whereas untreated and baricitinib-treated HT mice showed shorter survival; functional improvement was not observed. Our results also show that type I IFN signaling contributes to muscle inflammation and weakness, making it a key driver of muscle damage and thereby reinforcing its potential as a therapeutic target.
Authors
- Melissa Morales (ORCID: https://orcid.org/0000-0001-5681-5653)
- Joanna E. Parkes (ORCID: https://orcid.org/0000-0002-4007-240X)
- K. Nagaraju
- T.V. Sundar
- Karen Huang (ORCID: https://orcid.org/0000-0001-6633-5776)
- Sabrina Narvesen
- Deeva Robles Kuriplach
- Rita Spathis
- Alfredo Guzman
- Elizabeth Bagley
- Nandhana Sudhan
- Xinyu Jia
Institutions
- Binghamton University (US)
- Vesta Sciences (United States) (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-02-19
- DOI
- https://doi.org/10.1002/art.70096
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Myositis Association
- Cure JM Foundation